Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases: An Underutilized Strategy

Journal of Gastrointestinal Surgery

Volumn 17, Issue 11, 2013, Pages 1938-1946

  Parikh, Alexander A ^a,d   Ni, Shenghua ^a   Koyama, Tatsuki ^a   Pawlik, Timothy M ^b   Penson, David ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Colorectal cancer; Hepatic resection

Indexed keywords

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AFRICAN AMERICAN; AGE; AGED; ARTICLE; CANCER REGISTRY; CANCER STAGING; CAUCASIAN; COLORECTAL TUMOR; FEMALE; HUMAN; LIVER RESECTION; LIVER TUMOR; MALE; METASTASIS; MORTALITY; PATHOLOGY; STATISTICS; TIME; UNITED STATES; UTILIZATION REVIEW; VERY ELDERLY;

ADENOCARCINOMA; AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; SEER PROGRAM; TIME FACTORS; UNITED STATES;

EID: 84885956405     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2325-z     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Blumgart LH, Fong Y. Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg 1995; 32: 333-421.
3. Scheele J, Altendorf-Hofmann A. Resection of colorectal liver metastases. Langenbecks Arch Surg 1999; 384: 313-327.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a Cancer Journal for Clinicians 2010; 60: 277-300.
5. Nathan H, de Jong MC, Pulitano C et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg 2010; 210: 755-764, 764-756.
6. House MG, Ito H, Gonen M et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1, 600 patients during two decades at a single institution. J Am Coll Surg 2010; 210: 744-752, 752-745.
7. Aloia TA, Fahy BN, Fischer CP et al. Predicting poor outcome following hepatectomy: analysis of 2313 hepatectomies in the NSQIP database. HPB (Oxford) 2009; 11: 510-515.
8. Halfdanarson TR, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. Cancer J 2010; 16: 125-131.
9. Wagner AD, Arnold D, Grothey AA et al. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 2009; CD005392.
10. van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
11. Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14: 862-870.
12. Zuckerman DS, Clark JW. Systemic therapy for metastatic colorectal cancer: current questions. Cancer 2008; 112: 1879-1891.
13. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016.
14. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, 2003-2012. NCCN, Fort Washington, 2013.
15. Mayo SC, Heckman JE, Shore AD et al. Shifting trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis. Surgery 2011; 150: 204-216.
16. Cooper GS, Virnig B, Klabunde CN et al. Use of SEER-Medicare data for measuring cancer surgery. Medical Care 2002; 40: IV-43-48.
17. Warren JL, Harlan LC, Fahey A et al. Utility of the SEER-Medicare data to identify chemotherapy use. Medical care 2002; 40: IV-55-61.
18. Potosky AL, Warren JL, Riedel ER et al. Measuring complications of cancer treatment using the SEER-Medicare data. Medical care 2002; 40: IV-62-68.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987; 40: 373-383.
20. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. Journal of Clinical Epidemiology 2000; 53: 1258-1267.
21. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
22. Fong Y, Cohen AM, Fortner JG et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946.
23. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520; discussion 520-502.
24. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657; discussion 657-648.
25. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007; 109: 718-726.
26. Temple LK, Hsieh L, Wong WD et al. Use of surgery among elderly patients with stage IV colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2004; 22: 3475-3484.
27. Nagano Y, Nojiri K, Matsuo K et al. The impact of advanced age on hepatic resection of colorectal liver metastases. Journal of the American College of Surgeons 2005; 201: 511-516.
28. Nojiri K, Nagano Y, Tanaka K et al. Validity of hepatic resection of colorectal liver metastases in the elderly (75 years and older). Anticancer research 2009; 29: 583-588.
29. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
30. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
31. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
32. Nasti G, Ottaiano A, Berretta M et al. Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemother Pharmacol 2010; 66: 209-218.
33. Tabernero J, van Cutsem E, Diaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25: 5225-5232.
34. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-5334.
35. Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2009; 27: 3677-3683.
36. Kopetz S, Hoff PM, Morris JS et al. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 2009; 28(3): 453-459.
37. Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.
38. Brostjan C, Gebhardt K, Gruenberger B et al. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res 2008; 14: 2065-2074.
39. Taieb J, Artru P, Paye F et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 2005; 23: 502-509.
40. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.
41. Fernandez FG, Ritter J, Goodwin JW et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-853.
42. Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990.
43. Abraham A, Habermann EB, Rothenberger DA et al. Adjuvant chemotherapy for stage III colon cancer in the oldest old: results beyond clinical guidelines. Cancer 2013; 119: 395-403.
44. Bouvier AM, Minicozzi P, Grosclaude P et al. Patterns of adjuvant chemotherapy for stage II and III colon cancer in France and Italy. Dig Liver Dis 2013; 45(8): 687-691.
45. Lin CC, Virgo KS. Association between the availability of medical oncologists and initiation of chemotherapy for patients with stage III colon cancer. J Oncol Pract 2013; 9: 27-33.
46. Panchal JM, Lairson DR, Chan W, Du XL. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer. Clin Colorectal Cancer 2013; 12: 113-121.
47. van den Broek CB, Bastiaannet E, Dekker JW et al. Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients-a large population-based study from 1990 to 2008. Acta Oncol 2013; 52: 941-949.